Dr Agarwals Eye Hospital: Receipt of sanction from the Honble NCLT, Chennai bench towards the Scheme of Amalgamation between Dr.…
Dr Agarwals Eye Hospital (DRAGARWQ) filed a disclosure titled "Receipt of sanction from the Honble NCLT, Chennai bench towards the Scheme of Amalgamation between Dr. Agarwals Eye Hospital Limited and Dr. Agarwals Health Care Limited and its…". The company is…
What happened
Dr Agarwals Eye Hospital (DRAGARWQ) filed a disclosure with the exchanges on 5 October 2026 at 10:51 PM titled "Receipt of sanction from the Honble NCLT, Chennai bench towards the Scheme of Amalgamation between Dr. Agarwals Eye Hospital Limited and Dr. Agarwals Health Care Limited and its…".
Company snapshot
Dr Agarwals Eye Hospital is a small-cap company, with a market value of about ₹2,493 crore.
The stock last traded at ₹5,159, against a 52-week range of ₹4,600–₹6,059.7 (14.9% below the high).
Before this filing the shares had moved −2.8% over the month and +2.6% over three months. Average daily turnover over the last 20 sessions was about ₹1.11 crore.
Promoters held 72.67% at the end of Q1 FY27; 7.67% of promoter shares were pledged. Foreign institutions owned 2.24% and domestic institutions 2.05%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 117 | 17.3 | 36.72 |
| Q2 FY26 | 118 | 19.3 | 41.04 |
| Q3 FY26 | 116 | 17.3 | 35.76 |
| Q4 FY26 | 120 | 16.2 | 33.6 |
| Q1 FY27 | 143 | 23.4 | 48.38 |
What history shows
This is not the company's first m&a disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 1.3% on average the next trading day and was up 0.5% on average after five days (2 filings with price data).
Market-wide, 1,961 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 1 Jun 2026 | M&A | +1.3% | +0.5% |
| 1 Jun 2026 | M&A | +1.3% | +0.5% |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.